The House Committee on Oversight and Reform today launched a two-day hearing to examine pricing practices for some of the nation’s costliest drugs.

Testifying today were current and former executives from Celgene Corporation, Bristol Myers Squibb and Teva Pharmaceuticals.

Committee Chairwoman Carolyn Maloney, D-N.Y., yesterday released staff reports describing actions by Celgene and Bristol Myers Squibb to more than triple the price of a monthly course of the cancer drug Revlimid since 2005 to $16,023; and by Teva to raise the price of a yearly course of the multiple sclerosis drug Copaxone sevenfold since 1997 to nearly $70,000.

The committee plans to release additional staff reports tomorrow in conjunction with testimony from the top executives of Amgen, Mallinckrodt, and Novartis. Rep. Elijah Cummings, D-Md., who chaired the committee until his recent death, launched the investigation into drug prices last year.

Related News Articles

Headline
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation provides an incomplete picture of U.S. spending on health care while…
Blog
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation, “What drives health spending in the U.S. compared to other countries…
Headline
The House Committee on Oversight and Reform this week concluded a two-day hearing examining pricing practices for some of the nation’s costliest drugs. As…
Headline
The Food and Drug Administration yesterday released a final rule allowing states, territories and Indian tribes to establish programs to import certain…
Headline
President Trump yesterday issued a new executive order that seeks to lower prescription drug prices. The order directs the Secretary of Health and Human…
Headline
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug…